Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard J M, Ané M, Montastruc J L, Rascol A
Department of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse, France.
Mov Disord. 1994 Jul;9(4):437-40. doi: 10.1002/mds.870090410.
One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.
在两组帕金森病患者中，采用双盲、随机、交叉设计，将纳曲酮（100毫克/天）辅助治疗1个月与安慰剂进行比较。第一组由10例运动功能中度受损且单用溴隐亭治疗控制不佳的患者组成。第二组由8例左旋多巴诱发的剂峰异动症患者组成。与安慰剂相比，纳曲酮在两组中均未显示出运动功能有任何显著变化。这些阴性临床结果不支持内源性阿片系统在帕金森病运动障碍病理生理学中起重要作用。
